CA3003262C - Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation - Google Patents

Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation Download PDF

Info

Publication number
CA3003262C
CA3003262C CA3003262A CA3003262A CA3003262C CA 3003262 C CA3003262 C CA 3003262C CA 3003262 A CA3003262 A CA 3003262A CA 3003262 A CA3003262 A CA 3003262A CA 3003262 C CA3003262 C CA 3003262C
Authority
CA
Canada
Prior art keywords
seq
amino acid
galr2
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3003262A
Other languages
English (en)
Other versions
CA3003262A1 (fr
Inventor
Jae Young Seong
Jong-Ik Hwang
Dong-Hoon Kim
Gi Hoon Son
Yoo-Na LEE
Seongsik YUN
Arfaxad REYES-ALCARAZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuracle Science Co Ltd
Original Assignee
Neuracle Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuracle Science Co Ltd filed Critical Neuracle Science Co Ltd
Publication of CA3003262A1 publication Critical patent/CA3003262A1/fr
Application granted granted Critical
Publication of CA3003262C publication Critical patent/CA3003262C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un agoniste du récepteur de type 2 de la galanine basé sur la spexine, et une utilisation de ce dernier. Plus particulièrement, la présente invention concerne un agoniste peptidique présentant une spécificité et stabilité améliorées vis-à-vis du récepteur de type 2 de la galanine, l'agoniste peptidique étant impliqué dans la régulation de fonctions physiologiques de l'organisme dans lesquelles le récepteur de type 2 de la galanine joue un rôle, telles que l'alimentation, l'anxiété, l'émotion et l'addiction, permettant de ce fait de supprimer l'appétit, de soulager des troubles anxieux, et de diminuer l'addiction au plaisir, et, en conséquence, l'agoniste peptidique peut être utilisé pour prévenir ou traiter des maladies induites par le récepteur de type 2 de la galanine.
CA3003262A 2015-11-30 2016-11-30 Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation Active CA3003262C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0168555 2015-11-30
KR1020150168555A KR101885238B1 (ko) 2015-11-30 2015-11-30 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도
PCT/KR2016/013950 WO2017095132A1 (fr) 2015-11-30 2016-11-30 Agoniste du récepteur de type 2 de la galanine basé sur la spexine, et utilisation de ce dernier

Publications (2)

Publication Number Publication Date
CA3003262A1 CA3003262A1 (fr) 2017-06-08
CA3003262C true CA3003262C (fr) 2023-10-31

Family

ID=58797220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003262A Active CA3003262C (fr) 2015-11-30 2016-11-30 Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation

Country Status (9)

Country Link
US (3) US10385098B2 (fr)
EP (1) EP3384920A4 (fr)
JP (1) JP6619097B2 (fr)
KR (1) KR101885238B1 (fr)
CN (1) CN108348570B (fr)
AU (2) AU2016361783C1 (fr)
BR (1) BR112018008315A2 (fr)
CA (1) CA3003262C (fr)
WO (1) WO2017095132A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022287A (en) 1998-08-19 2000-02-08 General Motors Corporation Modularly constructed vehicular transmission
KR101885238B1 (ko) 2015-11-30 2018-08-06 주식회사 뉴라클사이언스 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도
KR102454460B1 (ko) 2017-06-27 2022-10-17 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
CN111154712B (zh) * 2020-01-10 2022-02-08 复旦大学附属华山医院 一种Spexin促进胰岛素的分泌和胰岛细胞增殖的方法
CN116751261B (zh) * 2023-06-29 2024-05-14 湖南中晟全肽生物科技股份有限公司 一种galr2激动剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972624A (en) 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
GB0403509D0 (en) 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
TWI515007B (zh) * 2006-01-05 2016-01-01 美國猶他大學研究基金會 改善以神經系統為標的之藥劑之性質之方法及組合物
WO2012042455A1 (fr) * 2010-09-28 2012-04-05 Actelion Pharmaceuticals Ltd Neuropeptide q utilisé comme modulateur de gpcr galr2 et ses utilisations
EP2627349B1 (fr) * 2010-10-15 2016-02-03 The Trustees of Columbia University in the City of New York Gènes de l'obésité, leurs protéines et leurs utilisations
EP2630091A1 (fr) 2010-10-20 2013-08-28 Poolrite Research Pty Ltd Procédé de désinfection de l'eau
WO2012102529A2 (fr) * 2011-01-24 2012-08-02 애니젠 주식회사 Composition pour la régulation des rythmes circadiens, composition pour le diagnostic de troubles du rythme circadien, et kit de diagnostic
KR101885238B1 (ko) 2015-11-30 2018-08-06 주식회사 뉴라클사이언스 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도

Also Published As

Publication number Publication date
CN108348570B (zh) 2022-05-03
EP3384920A1 (fr) 2018-10-10
EP3384920A4 (fr) 2019-05-08
US20220242910A1 (en) 2022-08-04
US20180319841A1 (en) 2018-11-08
AU2019202918A1 (en) 2019-05-16
US10385098B2 (en) 2019-08-20
AU2019202918B2 (en) 2020-04-30
CN108348570A (zh) 2018-07-31
JP6619097B2 (ja) 2019-12-11
JP2018537444A (ja) 2018-12-20
CA3003262A1 (fr) 2017-06-08
AU2016361783B2 (en) 2019-02-07
US20200010509A1 (en) 2020-01-09
KR101885238B1 (ko) 2018-08-06
AU2016361783C1 (en) 2019-06-06
US11248023B2 (en) 2022-02-15
WO2017095132A1 (fr) 2017-06-08
AU2016361783A1 (en) 2018-05-10
KR20170062848A (ko) 2017-06-08
BR112018008315A2 (pt) 2018-10-30

Similar Documents

Publication Publication Date Title
US11248023B2 (en) Agonist of spexin-based galanin type 2 receptor and use thereof
Garnham et al. The chemical complexity of cellular microtubules: tubulin post‐translational modification enzymes and their roles in tuning microtubule functions
EP3577462B1 (fr) Interaction entre les peptides-c et le récepteur de l'elastine, un modèle pour comprendre la maladie vasculaire
US20100105625A1 (en) Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders
Lamothe et al. Chapter five-ubiquitination of ion channels and transporters
JP7009364B2 (ja) ホモシスチン尿症の治療する組成物および方法
CN114026114A (zh) 用于治疗再灌注损伤的bnip3肽
AU2012272550B2 (en) Prevention and treatment of acute inflammatory conditions
US20150087604A1 (en) Anti-fatty acid synthase polypeptide and use thereof
JP2010229093A (ja) 新規ＣｈｅｍｅｒｉｎＲアゴニスト
KR101885241B1 (ko) 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도
WO2012006640A2 (fr) Compositions et procédés utiles dans la stimulation de la mémoire
JP2021020900A (ja) 糖代謝異常改善剤
US10247735B2 (en) Compositions and methods for regulating glucose metabolism
WO2014014819A2 (fr) Méthodes de traitement de troubles du métabolisme du glucose
WO2006070804A1 (fr) Procede inhibant l’activite de la telomerase et inhibiteur
WO2024102077A1 (fr) Compositions et méthodes pour le traitement de l'obésité
US20030027171A1 (en) Cell cycle regulator protein
Tang et al. The glycogen cargo receptor STBD1: from biology to disease targeted therapies
De Francesco Structural and functional mechanisms of Aceruloplasminemia
TW201234009A (en) Pharmaceutical composition of regulating the expression level of survival of motor neuron 1 and method of detecting enzyme activity of ubiquitin carboxyl-terminal hydrolase L1 in human fibroblasts

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425

EEER Examination request

Effective date: 20180425